Pasithea Therapeutics

Pasithea Therapeutics EBITDA per Share

The EBITDA per Share of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is -2.97 USD. In the previous year, EBITDA per Share was -13.00 USD — a change of -77.18% (higher).

EBITDA per Share

-2.97USD

YoY

-77.18%

Last updated:

EBITDA per Share of Pasithea Therapeutics is 2025 -2.97 USD. EBITDA per Share of Pasithea Therapeutics was 2024 -13.00 USD. It decreases by -77.18% higher compared to the previous year.

The Pasithea Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2020
-0.16 USD
Jan 1, 2021
-3.92 USD
Jan 1, 2022
-9.67 USD
Jan 1, 2023
-15.34 USD
Jan 1, 2024
-13.00 USD
Jan 1, 2025
-2.97 USD
The Pasithea Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-2.97USD-77.18%
-13.00USD-15.26%
-15.34USD+58.69%
-9.67USD+146.74%
-3.92USD+2,301.51%
-0.16USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

EBITDA per Share of Pasithea Therapeutics is -2.97 USD in 2025.

EBITDA per Share of Pasithea Therapeutics changed from -13.00 USD to -2.97 USD, representing a -77.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics